CANDEL THERAPEUTICS, INC. Income (Loss) from Continuing Operations before Income Taxes, Domestic
CANDEL THERAPEUTICS, INC. (CADL) reported Income (Loss) from Continuing Operations before Income Taxes, Domestic of -$38.18 million for the 12-month period ending 2025-12-31, per its 10-K filed 2026-03-12.
Financial Statements › Income Statement › Pre-tax Income
us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic · last filed 2026-03-12
- CANDEL THERAPEUTICS, INC. income (loss) from continuing operations before income taxes, domestic for fiscal 2025 was -$38.18M.
- CANDEL THERAPEUTICS, INC. income (loss) from continuing operations before income taxes, domestic for fiscal 2024 was -$55.18M.
| Period end | Income (Loss) from Continuing Operations before Income Taxes, Domestic 12 month |
|---|---|
| 2025-12-31 | -$38.18M 10-K · filed 2026-03-12 |
| 2024-12-31 | -$55.18M 10-K · filed 2026-03-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Sana Biotechnology, Inc. (SANA) | United States | $0.886B | -4.92 |
| Attovia Therapeutics, Inc. (ATTO) | United States | $0.828B | |
| Odyssey Therapeutics, Inc. (ODTX) | United States | $0.960B | |
| Solid Biosciences Inc. (SLDB) | United States | $0.802B | -5.07 |
| Cullinan Therapeutics, Inc. (CGEM) | United States | $0.993B | -5.72 |
| Monte Rosa Therapeutics, Inc. (GLUE) | United States | $1.002B | -12.81 |
| 4D Molecular Therapeutics, Inc. (FDMT) | United States | $0.733B | -4.10 |
| MeiraGTx Holdings plc (MGTX) | United States | $1.061B | 16.10 |
| Vor Biopharma Inc. (VOR) | United States | $1.091B | 1.60 |
| Aura Biosciences, Inc. (AURA) | United States | $0.639B | -5.61 |